Heart Failure is a progressive disease state previously manageable only by guideline directed medical therapy (GDMT). Many patients are often left without options in their heart failure treatment and require additional screening to determine whether they are a candidate for available device therapy. This webinar will give an overview of the Optimizer® CCM® therapy delivery system, the indications for use, and share best practices on how to screen patients that may benefit from CCM®. Case studies will be shown to emphasize the need for patient screening, as well as give the audience real world examples of how to implement CCM® therapy in your practice and access to your patients.

Experts don't necessarily agree!

New device-based options for treating heart failure have arrived - and the indications for their appropriate use occasionally overlap.

This webinar will provide an upbeat and lively discussion between experienced users of each of the current device-based therapeutic options for moderate to severe heart failure. Each faculty member will provide an overview of their specific technology, present the clinical evidence, highlight procedural safety issues (if any), and define indication-based screening processes for appropriate patients.

The device technologies that will be reviewed include: Cardiac Contractility Modulation (Optimizer® Smart), Cardiac Resynchronization Therapy (CRT), and Baroreflex Activation Therapy (BAT). After each presentation the faculty will debate appropriate patient selection.

The importance of accurately assessing the NYHA classification of patients with Heart Failure has never been higher! For almost two decades, the only device available to treat Heart Failure have been cardiac resynchronization (CRT) devices. But now everything has changed. The FDA has approved a breakthrough device for the treatment of Heart failure, and the ability to utilize it depends heavily on accurate NYHA assessment. This treatment can address the almost 1.2M patients who are not candidates for CRT in the US, but only if cardiologists can identify and refer them appropriately. This lecture will explain what Cardiac Contractility Modulation therapy is, how it works, and what you can expect in terms of outcomes when utilizing this treatment for NYHA Class III patients who remain symptomatic in spite of guideline directed medical therapy. The faculty will share their personal experiences and what they have learned about CCM® therapy using case-based examples that include the means by which they have increased their awareness of how to identify appropriate candidates for this important new device therapy for patients with heart failure who have few or no other options.